Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK

OBJECTIVES: Budesonide/formoterol (BF) Spiromax(®) is an inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We e...

Descripción completa

Detalles Bibliográficos
Autores principales: Voorham, Jaco, Roche, Nicolas, Benhaddi, Hicham, van der Tol, Marianka, Carter, Victoria, van Boven, Job F.M., Bjermer, Leif, Miravitlles, Marc, Price, David B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Respiratory Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224753/
https://www.ncbi.nlm.nih.gov/pubmed/30368448
http://dx.doi.org/10.1136/bmjopen-2018-022051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224753/
https://www.ncbi.nlm.nih.gov/pubmed/30368448
http://dx.doi.org/10.1136/bmjopen-2018-022051

Ejemplares similares